Alteration of hepatic proinflammatory cytokines is involved in the resveratrol- mediated chemoprevention of chemically-induced hepatocarcinogenesis

Current Pharmaceutical Biotechnology

Volumn 13, Issue 1, 2012, Pages 229-234

  Mbimba, Thomas ^a   Awale, Prabha ^a   Bhatia, Deepak ^a   Geldenhuys, Werner J ^a   Darvesh, Altaf S ^a   Carroll, Richard T ^a   Bishayee, Anupam ^a,b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b Northeastern Ohio Medical University   (United States)

Author keywords

Diethylnitrosamine; Hepatocarcinogenesis; IL 1 ; IL 6; Inflammation; Liver; Resveratrol; TNF

Indexed keywords

DIETHYLNITROSAMINE; INTERLEUKIN 1; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; RESVERATROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; CHEMOPROPHYLAXIS; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; INFLAMMATION; LIVER CARCINOGENESIS; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VASCULARIZATION;

ANIMALS; ANTICARCINOGENIC AGENTS; CYTOKINES; DIETHYLNITROSAMINE; FEMALE; GENE EXPRESSION REGULATION; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; PHENOBARBITAL; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; STILBENES;

RATTUS; VITACEAE;

EID: 84855860394     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112798868575     Document Type: Article

References (49)

1. Schütte, K.; Bornschein, J.; Malfertheiner, P. Hepatocellular carcinoma-epidemiological trends and risk factors. Dig. Dis., 2009, 27, 80-92.
2. Jemal, A.; Siegel, A.; Xu, J.; Ward, E. Cancer statistics. C.A. Cancer J. Clin., 2010, 60, 1-24.
3. Bartsch, H.; Montesano, R. Relevance of nitrosamines to human cancer. Carcinogenesis, 1984, 5, 1381-1393.
4. Kensler, T.W.; Egner, P.A.; Wang, J.B.; Zhu, Y.R.; Zhang, B.C.; Lu, P.X.; Chen, J.G. Qian, G.S.; Kuang, S.Y.; Jackson, P.E.; Gange, S.J.; Jacobson, L.P.; Muñoz, A.; Groopman, J.D. Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterology, 2004, 127, S310-S318.
5. Berasain, C.; Casillo, J.; Perugorria, M.J.; Latasa, M.U.; Prieto, J.; Avila, M.A. Inflammation and liver cancer: new molecular links. Ann. N.Y. Acad. Sci., 2009, 1155, 206-221.
6. Pang, R.; Tse, E.; Poon, R.T.P. Molecular pathways in hepatocellular carcinoma. Cancer Lett., 2006, 240, 157-169.
7. Senthil, M.; Mailey, B.; Leong, L.; Chung, V.; Yen, Y.; Chen, Y.J.; Max, H.; Kim, J. Liver-directed regional therapy in the multidisciplinary management of hepatocellular cancer. Curr. Cancer Ther. Rev., 2010, 6, 19-25.
8. Je, Y.; Schutz, F.A.B.; Choueiri, T.K. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and mata-analysis of clinical trials. Lancet Oncol., 2009, 10, 967-974.
9. Rahman, I.; Biswas, S.K.; Kirkham, P.A. Regulation of inflammation and redox signaling by dietary polyphenols. Biochem. Pharmacol., 2005, 72, 1439-1452.
10. Naithani, R.; Huma, L.C.; Moriarty, R.M.; McCormick, D.L.; Mehta, R.G. Comprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trials. Curr. Med. Chem., 2008, 15, 1044-1071.
11. Korkina, L.G.; De Luca, C.; Kostyuk, V.A.; Pastore, S. Plant polyphenols and tumors: from mechanisms to therapies, prevention, and protection against toxicity of anti-cancer treatments. Curr. Med. Chem., 2009, 16, 3943-3965.
12. Kim, Y.S.; Young, M.R.; Bobe, G.; Colbum, N.H.; Milner, J.A. Bioactive food components, inflammatory targets, and cancer prevention. Cancer Prev. Res., 2009, 2, 200-208.
13. Aggarwal, B.B.; Bhardwaj, A.; Aggarwal, R.S.; Seeram, N.P.; Shishodia, S.; Takada, Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res., 2004, 24, 2783-2840.
14. Bishayee, A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev. Res., 2009, 2, 409-418.
15. Bishayee, A.; Politis, T.; Darvesh, A.S. Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat. Rev., 2010, 36, 43-53.
16. Bishayee, A.; Dhir, N. Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. Chem.-Biol. Interact., 2009, 179, 131-144.
17. Bishayee, A.; Waghray, A.; Barnes, K.F.; Mbimba, T.; Bhatia, D.; Chatterjee, M.; Darvesh, A.S. Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis. Pharm. Res., 2010, 27, 1080-1091.
18. Bishayee, A.; Barnes, K.F.; Bhatia, D.; Darvesh, A.S. and Carroll, R.T. Resveratrol suppresses oxidative stress and inflammatory response in diethylnitrosamine-initiated rat hepatocarcinogenesis. Cancer Prev. Res., 2010, 3, 753-763.
19. Kundu, J.K.; Surh, Y.-J. Inflammation: gearing the journey to cancer. Mutat. Res., 2008, 659, 15-30.
20. Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-related inflammation. Nature, 2008, 454, 436-444.
21. Schetter, A.J.; Heegaard, N.H.H.; Harris, C.C. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis, 2010, 31, 37-49.
22. Naugler, W.E.; Sakurai, T.; Kim, S.; Maeda, S.; Kim, K.H.; Elsharkawy A.M.; Karin, M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science, 2007, 317, 121-124.
23. Rogers, A.B.; Theve, E.J.; Feng, Y.; Fry, R.C.; Taghizadeh, K.; Clapp, K.M.; Boussahmain, C.; Cormier, K.S.; Fox, J.G. Hepatocellular carcinoma associated with liver-gender disruption in male mice. Cancer Res., 2007, 67, 11536-11546.
24. Muriel, P. NF-κB in liver diseases: a target for drug therapy. J. Appl. Toxicol., 2009, 29, 91-100.
25. Mann, C.D.; Neal, C.P.; Garcea, G.; Manson, M.M. Dennison, A.R.; Berry, D.P. Phytochemicals as potential chemopreventive and chemotherapeutic agents in hepatocarcinogenesis. Eur. J. Cancer Prev., 2009, 18, 13-25.
26. Bishayee, A.; Waghray, A.; Patel, M.A.; Chatterjee, M. Vanadium in the detection, prevention and treatment of cancer: the in vivo evidence. Cancer Lett., 2010, 294, 1-12.
27. Darvesh, A.S.; Bishayee, A. Selenium in the prevention and treatment of hepatocellular carcinoma. Anticancer Agents Med. Chem., 2010, 10, 338-345.
28. Andus, T.; Bauer, J.; Gerok, W. Effects of cytokines on the liver. Hepatology, 1991, 13, 364-375.
29. Hunt, J.S.; Chen, H.L., Hu, X.L., Chen, T.Y.; Morrison, D.C. Tumor necrosis factor-nnngene expression in the tissues of normal mice. Cytokine, 1992, 4, 340-346.
30. Wodemann, M., Fandrey, J.; Jelkmann, W. Tumor necrosis factor-α production by human hepatoma cell lines is resistant to drugs that are inhibitory to macrophages. J. Interferon Cytokine Res., 1998, 18, 1069-1075.
31. Yang, H.; Bocchetta, M.; Kroczynska, B.; Elmishad, A.G.; Chen, Y.; Liu, Z.; Bubici, C.; Mossman, B.T.; Pass, H.I.; Testa, J.R.; Franzoso, G.; Carbone, M. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc. Natl. Acad. Sci. USA., 2006, 103, 10397-10402.
32. Ayada, M.; Ishikawa, T.; Okumura, A.; Tanabe, J.; Ito, H.; Ohashi, T.; Matsumoto, E.; Sato, K.; Hotta, N.; Fukuzawa, Y.; Kakumu, S. Alteration of serum cytokine balances among different phases of chronic hepatitis B virus infection. Hepatol. Res., 2006, 34, 214-221.
33. Cheng, K.-S.; Tang, H.-L.; Chou, F.-T.; Chou, J.-W.; Hsu, C.-H.; Yu, C.-J.; Kao, S.-T.; Li, T.-C. Cytokine evaluation in liver cirrhosis and hepatocellular carcinoma. Hepato-Gastroenterology, 2009, 56, 1105-1110.
34. Tsuchiya, M.; Kono, H.; Matsuda, M.; Fujii, H.; Rusyn, I. Protective effect of Juzen-taiho-to on hepatocarcinogenesis is mediated through the inhibition of Kupffer cell-induced oxidative stress. Int. J. Cancer, 2008, 123, 2503-2511.
35. Wang, Y.; Ausman, L.M.; Greenberg, A.S.; Russell, R.M.; Wang, X.-D. Dietary lycopene and tomato extract supplementations inhibit nonalcoholic steatohepatitis-promoted hepatocarcinogenesis in rats. Int. J. Cancer, 2010, 126, 1788-1796.
36. Apte, R.N.; Voronov, E. Interleukin-1-a major pleiotropic cytokine in tumor-host interactions. Semin. Cancer Biol., 2002, 12, 277-290.
37. Chen, C.C.; Yang, S.Y.; Liu, C.J.; Lin, C.L.; Liaw, Y.F.; Lin, S.M.; Lee, S.D.; Chen, P.J.; Chen, C.J.; Yu, M.W. Association of cytokine and DNA repair gene polymorphisms with hepatitis B-related hepatocellular carcinoma. Int. J. Epidemiol., 2005, 34, 1310-1318.
38. Tsutsumi, T.; Suzuki, T.; Moriya, K.; Yotsuyanagi, H.; Shintani, Y.; Fujie, H.; Matsuura, Y.; Kimura, S.; Koike, K.; Miyamura, T. Alteration of interhepatic cytokine expression and AP-1 activation in transgenic mice expressing hepatitis C virus core protein. Virology, 2002, 304, 415-424.
39. Yamada, Y.; Karasaki, H.; Matsushima, K.; Lee, G.H.; Ogawa, K. Expression of an IL-1 receptor antagonist during mouse hepatocarcinogenesis demonstrated by differential display analysis. Lab. Invest., 1999, 79, 1059-1067.
40. Lázár-Molnár, E.; Hegyesi, H.; Tóth, S.; Falus, A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine, 2000, 12, 547-554.
41. Lin, W.W.; Karin, M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest., 2007, 117, 1175-1183.
42. Taub, R. Hepatoprotection via the IL-6/Stat3 pathway. J. Clin. Invest., 2003, 112, 978-980.
43. Jin, X.; Zimmers, T.A., Perez, E.A.; Pierce, R.H.; Zhang, Z.; Koniaris, L.G. Paradoxical effects of short-and long-term interleukin-6 exposure on liver injury and repair. Hepatology, 2006, 43, 478-484.
44. Porta, C.; De Amici, M.; Quaglini, S.; Paglino, C.; Tagliani, F.; Boncimino, A.; Moratti, R.; Corazza, G.R. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann. Oncol., 2008, 19, 353-358.
45. Wong, V.W.; Yu, J.; Cheng, A.S.; Wong, G.L.; Chan, H.Y.; Chu, E.S.; Ng, E.K.; Chan, F.K.; Sung, J.J.; Chan, H.L. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int. J. Cancer. 2009, 124, 2766-2770.
46. Nakagawa, H.; Maeda, S.; Yoshida, H.; Tateishi, R.; Masuzaki, R.; Ohki, T.; Hayakawa, Y.; Kinoshita, H.; Yamakado, M.; Kato, N.; Shiina, S.; Omata, M. Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences. Int. J. Cancer, 2009, 125, 2264-2269.
47. Nussler, A.K.; Di Silvio, M.; Liu, Z.Z.; Geller, D.A.; Freeswick, P.; Dorko, K.; Bartoli, F.; Billiar T.R. Further characterization and comparison of inducible nitric oxide synthase in mouse, rat, and human hepatocytes. Hepatology, 1995, 21, 1552-1560.
48. 2 secretion in human peripheral blood mononuclear cells. Nutr Res., 2008, 28, 321-328.
49. Aung, H.T.; Schroder, K.; Himes, S.R.; Brion, K.; van Zuylen, W.; Trieu, A.; Suzuki, H.; Hayashizaki, Y.; Hume, D.A.; Sweet, M.J.; Ravasi, T. LPS regulates proinflammatory gene expression in macrophages by altering histone deacetylase expression. FASEB J., 2006, 20, 1315-1327.